EGFR and breast carcinoma: Other examples of biomarkers used in current therapies include epidermal growth factor receptor (EGFR) inhibitors for non-small cell lung cancer patients with EGFR mutations and PARP inhibitors in cancers with Breast Cancer Gene 1/2 (BRCA1/2) mutations.